Premium
DT‐01‐05: High Dose Donepezil with Solifenacin (CPC‐201) Improves Safety and Initial Efficacy in Alzheimer’s Disease
Author(s) -
Chase Thomas N.,
Clarence-Smith Kathleen
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.011
Subject(s) - donepezil , solifenacin , anticholinergic , medicine , tolerability , clinical endpoint , adverse effect , pharmacology , population , dementia , urology , clinical trial , disease , overactive bladder , alternative medicine , pathology , environmental health
neurodegeneration for the initial 2-year continuous treatment period. Hippocampal, whole-brain, and ventricular volumes were assessed. Results include significantly less total hippocampal atrophy and significant effects on other measures in the active compared to the control group. Conclusions: The initial 2-year multi-nutrient intervention showed reduced atrophy in the brain. These cerebral biological and structural changes are consistent with the observed clinical and cognitive benefits in prodromal AD and support the previous proposition that intervention as early as prodromal ADmay result in increased effectiveness of such therapeutic interventions. Funding: EUFP7, project LipiDiDiet, Grant Agreement N 211696.